☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Elicio Therapeutics
Elicio Therapeutics Report the First Patient Dosing of ELI-002 7P in P-I/II Trial for KRAS/NRAS Mutated Solid Tumors
April 28, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Elicio Therapeutics Entered into a Definitive Merger Agreement with Angion to Advance ELI-002 for Cancer
January 18, 2023
Load more...
Back to Home